Date	Title	View
January 8, 2021	Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 7, 2021	Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference